Lintuzumab AC 225
Lin-AC225-MM01
Phase 1 small_molecule terminated
Quick answer
Lintuzumab AC 225 for Refractory Multiple Myeloma is a Phase 1 program (small_molecule) at Actinium Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Actinium Pharmaceuticals
- Indication
- Refractory Multiple Myeloma
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- terminated